Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D 2 dopamine receptor

British Journal of Pharmacology

Volumn 161, Issue 6, 2010, Pages 1343-1350

  Kara, Elodie ^a   Lin, Hong ^a   Svensson, Kjell ^b   Johansson, Anette M ^b   Strange, Philip G ^a  

^a UNIVERSITY OF READING   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

ACR16; Allosteric effects; D 2 dopamine receptor; Dopamine stabilizers; OSU6162; Radioligand binding; Stimulation of 35S GTP S binding

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; 4 (3 METHANESULFONYL PHENYL) 1 PROPYL PIPERIDINE; ACR 16; AMPHETAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); PROPYLNORAPOMORPHINE; SODIUM ION; SPIPERONE; SULFUR 35; TRITIUM; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; LOCOMOTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE AGONISTS; HUMANS; PIPERIDINES; PROTEIN BINDING; RECEPTORS, DOPAMINE D2;

EID: 78049392648     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01010.x     Document Type: Article

References (22)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41: 237-260.
3. Castro SW, Strange PG (1993). Differences in the ligand binding properties of the short and long versions of the D2 dopamine receptor. J Neurochem 60: 372-375.
4. Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
5. Ekesbo A, Torstenson R, Hartvig P, Carlsson A, Sonesson C, Waters N et al. (1999). Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains. Neuropharmacology 38: 331-338.
6. Han Y, Moreira IS, Urizar E, Weinstein H, Javitch JA (2009). Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol 5: 688-695.
7. Hayes G, Biden TJ, Selbie LA, Shine J (1992). Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line. Mol Endocrinol 6: 920-926.
8. Kara E, Lin H, Strange PG (2009). Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics. J Neurochem 112: 1442-1453.
9. Lahti RA, Tamminga CA, Carlsson A (2007). Stimulating and inhibitory effects of the dopamine 'stabilizer' (-)-OSU6162 on dopamine D(2) receptor function in vitro. J Neural Transm 114: 1143-1146.
10. Lin H, Saisch SG, Strange PG (2006). Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor. Br J Pharmacol 149: 291-299.
11. Lowry O, Rosebrough N, Farr A, Randall R (1951). Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275.
12. Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM et al. (2006). The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 318: 810-818.
13. Nichols NF, Cimini MG, Haas JV, Staton BA, Tedroff J, Svensson KA (2002). PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease. Neuropharmacology 43: 817-824.
14. Nilsson M, Carlsson A, Markinhuhta KR, Sonesson C, Pettersson F, Gullme M et al. (2004). The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition. Prog Neuropsychopharmacol Biol Psychiatry 28: 677-685.
15. Nunnari JM, Repaske MG, Brandon S, Cragoe EJ, Jr, Limbird LE (1987). Regulation of porcine brain alpha 2-adrenergic receptors by Na+, H+ and inhibitors of Na+/H+ exchange. J Biol Chem 262: 12387-12392.
16. Roberts DJ, Lin H, Strange PG (2004). Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors. Biochem Pharmacol 67: 1657-1665.
17. Rung JP, Rung E, Helgeson L, Johansson AM, Svensson K, Carlsson A et al. (2008). Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Transm 115: 899-908.
18. Seeman P, Guan HC (2007). Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis. Eur J Pharmacol 557: 151-153.
19. Sonesson C, Lin CH, Hansson L, Waters N, Svensson K, Carlsson A et al. (1994). Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. J Med Chem 37: 2735-2753.
20. Strange PG (2001). Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 53: 119-133.
21. Strange PG (2008). Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol Sci 29: 314-321.
22. 2 dopamine receptor that adopts the active conformation. J Neurochem 77: 493-504.